Last reviewed · How we verify
Desogestrel ovulatory phase
Desogestrel is a progestin that prevents ovulation by suppressing the luteinizing hormone surge and thickening cervical mucus to inhibit sperm penetration.
Desogestrel is a progestin that prevents ovulation by suppressing the luteinizing hormone surge and thickening cervical mucus to inhibit sperm penetration. Used for Ovulation prevention for contraception.
At a glance
| Generic name | Desogestrel ovulatory phase |
|---|---|
| Sponsor | Centre Hospitalier Intercommunal Creteil |
| Drug class | Progestin (hormonal contraceptive) |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
Desogestrel is a third-generation synthetic progestin used in hormonal contraceptives. It acts primarily by inhibiting the gonadotropin-releasing hormone (GnRH)-driven surge of luteinizing hormone (LH) that triggers ovulation. Additionally, it increases cervical mucus viscosity, creating a barrier to sperm transport, and alters the endometrium to reduce implantation likelihood.
Approved indications
- Ovulation prevention for contraception
Common side effects
- Headache
- Nausea
- Breast tenderness
- Irregular bleeding
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desogestrel ovulatory phase CI brief — competitive landscape report
- Desogestrel ovulatory phase updates RSS · CI watch RSS
- Centre Hospitalier Intercommunal Creteil portfolio CI